Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.

The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Latest Announcements


04/08/2016
USPTO Grants Allowances for Two PTX-200 Patents
20/07/2016
Change to Exercise Price of Options
20/07/2016
Amended Share Trading Policy
20/07/2016
June 2016 Appendix 4C – Quarterly
12/07/2016
Shortfall Placement Oversubscribed
30/06/2016
Completion of Entitlement Issue Allotment and Appendix 3B